Results 251 to 260 of about 28,483 (297)

Alteplase

Expert Opinion on Investigational Drugs, 1997
Alteplase (recombinant human tissue type plasminogen activator, rt-PA) was identified as a naturally occurring plasminogen activator in 1975, cloned from a human melanoma cell line in 1981, introduced into clinical trials in 1982, and received a product licence for the treatment of acute myocardial infarction in 1986.
openaire   +2 more sources

Alteplase and Thrombectomy — Not a Bridge to Dismantle

New England Journal of Medicine, 2021
In the past few years, thrombectomy — the removal of a thrombus under angiographic guidance — has become an accepted treatment for acute ischemic stroke caused by occlusion of a large cerebral vess...
openaire   +3 more sources

Reteplase versus Alteplase for Acute Ischemic Stroke.

New England Journal of Medicine
BACKGROUND Alteplase is the standard agent used in early reperfusion therapy, but alternative thrombolytic agents are needed. The efficacy and safety of reteplase as compared with alteplase in patients with acute ischemic stroke are unclear. METHODS We
Shuya Li, Hongqiu Gu, Hao Li, Xuechun Wang, A. Jin, Shuming Guo, Guozhi Lu, Fengyuan Che, Weiwei Wang, Yan Wei, Yilong Wang, Zixiao Li, Xia Meng, Xing-fu Zhao, Liping Liu, Yongjun Wang   +15 more
semanticscholar   +1 more source

Tenecteplase vs Alteplase for Patients With Acute Ischemic Stroke: The ORIGINAL Randomized Clinical Trial.

Journal of the American Medical Association (JAMA)
Importance Tenecteplase is a bioengineered variant of alteplase with greater fibrin specificity and a longer half-life, allowing single-bolus administration.
Xia Meng, Shuya Li, Hongguo Dai, Guozhi Lu, Weiwei Wang, Fengyuan Che, Yu Geng, Minghui Sun, Xiyan Li, Hao Li, Yongjun Wang   +10 more
semanticscholar   +1 more source

Tenecteplase vs Alteplase in Acute Ischemic Stroke Within 4.5 Hours

Neurology
Background and Objectives The current European Stroke Organisation expedited recommendation on tenecteplase (TNK) for acute ischemic stroke (AIS) advocates that TNK 0.25 mg/kg can be used alternatively to alteplase (tissue plasminogen activator [TPA ...
L. Palaiodimou, A. Katsanos, Guillaume Turc, Alexandros-Georgios Asimakopoulos, Dimitrios Mavridis, P. D. Schellinger, Aikaterini Theodorou, Robin Lemmens, Simona Sacco, A. Safouris, M. Katan, A. Sarraj, U. Fischer, G. Tsivgoulis   +13 more
semanticscholar   +1 more source

Alteplase for ischaemic stroke

The Lancet, 2014
Vasilis Kontis and colleagues in their study (Aug 2, p 427) provided much needed estimates of the potential to lower premature mortality of four main non-communicable diseases (NCDs) by addressing six risk factors. These factors are part of a larger set of targets and indicators defi ned in WHO’s NCD Global Monitoring Framework (GMF) to meet the 25×25 ...
openaire   +3 more sources

Alteplase for the Treatment of Pulmonary Embolism

Advanced Emergency Nursing Journal, 2015
Pulmonary embolism can present with a wide range of symptoms, from asymptomatic to cardiac arrest, making diagnosis challenging. Alteplase is a fibrinolytic that is indicated for the treatment of pulmonary embolism in intermediate- and high-risk patients.
Christopher A. Paciullo, Nicholas A. Peters   +1 more
openaire   +3 more sources

Alteplase and tenecteplase: Applications in the peripheral circulation

Techniques in Vascular and Interventional Radiology, 2001
Alteplase (t-PA), a recombinant analogue of human tissue plasminogen activator, became the first genetically engineered thrombolytic approved by the Food and Drug Administration in 1987 for acute myocardial infarction (AMI). In addition to AMI, alteplase is currently approved for the treatment of acute ischemic stroke and pulmonary embolism, and we ...
Koji Sugimoto, Koji Sugimoto, Charles P. Semba, Charles P. Semba, Mahmood K. Razavi, Mahmood K. Razavi   +5 more
openaire   +3 more sources

Association of Time to Thrombolysis With Early Reperfusion After Alteplase and Tenecteplase in Patients With Large Vessel Occlusion.

Neurology
BACKGROUND AND OBJECTIVES Early treatment with intravenous alteplase increases the probability of lytic-induced reperfusion in large vessel occlusion (LVO) patients.
V. Yogendrakumar, J. Beharry, Leonid Churilov, L. Pesavento, Khairuinnisa Alidin, Melissa Ugalde, L. Weir, Peter J Mitchell, T. Kleinig, N. Yassi, Vincent N Thijs, Teddy Y Wu, H. Brown, H. Dewey, T. Wijeratne, Bernard Yan, G. Sharma, Patricia M. Desmond, Mark W. Parsons, G. Donnan, S. Davis, B. Campbell   +21 more
semanticscholar   +1 more source

Pharmacokinetics of alteplase in the treatment of ischaemic stroke

Expert Opinion on Drug Metabolism & Toxicology, 2012
Alteplase is the only approved drug for thrombolysis in acute ischaemic stroke (AIS) after its initial use in acute myocardial infarction (AMI). Its role in functional recovery is time-dependent while its major adverse effect, intracranial haemorrhage, is dose-dependent.
Paul Acheampong, Gary A. Ford
openaire   +3 more sources